FDA Authorizes JUUL2 and Its Tobacco and Menthol Pods — a Marketing Order, Not an Approval

The Food and Drug Administration has issued marketing granted orders for the JUUL2 System and its tobacco and menthol pods at 1.6% nicotine (18 mg/mL), deciding under premarket tobacco applications submitted in 2023 that marketing the products is, in the agency's words, appropriate for the protection of the public health. The orders, dated August 27, 2026, cover both the device and the two pod flavors.

The distinction matters and is worth stating plainly: this is a marketing authorization, not an FDA approval. No e-cigarette is FDA-approved in the drug-safety sense; the agency is permitting these products to be legally marketed after weighing their risks and benefits to the population as a whole.

On the evidence side, the agency pointed to behavioral studies in which a substantial proportion of adults who smoke completely switched away from cigarettes — up to 34.6% for the tobacco pod and 49.3% for the menthol pod at six weeks. With these orders, the FDA has now authorized 48 e-cigarette products in total.

The JUUL2 platform itself is U.S.-engineered and U.S.-manufactured, with a PodID anti-counterfeit chip and an optional age-gated app with device lock. For the vapor industry, the decision is the biggest regulatory signal since the PMTA process began: the market leader's flagship is back on legal shelves, and the compliance bar for everyone else just got a lot clearer.